Reaction

Otitis Media reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,269 reports · 133 co-occurring drugs

As of the last recalculation, Otitis Media appears in 3,269 FAERS reports alongside 133 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 33.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Dimenhydrinate5533.433.6
Botulinum Toxin Type A5026.026.1
Ampicillin3224.824.9
Ampicillin Sodium3224.824.9
Valproate Sodium5517.217.3
Palivizumab3313.813.8
Canakinumab2313.613.7
Ciclesonide2712.712.7
Gentamicin Sulfate3012.212.2
Cephalexin3911.611.6
Acetaminophen And Codeine2111.011.1
Diphenhydramine Hydrochloride Capsule, Liquid Filled3610.810.9
Cefuroxime1910.610.7
Nystatin4410.410.4
Nystatin Ointment4210.310.3
Nystatin Cream4210.310.3
Mercaptopurine2710.010.0
Ketoconazole269.69.6
Cimetidine149.39.3
Promethazine Hydrochloride269.09.0
Amoxicillin1028.78.8
Cyclobenzaprine Hydrochloride128.58.5
Vigabatrin198.38.4
Lidocaine Hydrochloride778.38.3
Amphotericin B168.28.2
Ganciclovir138.18.1
Methylprednisolone Acetate108.08.0
Cyclobenzaprine617.97.9
Ganciclovir Sodium137.87.9
Bendamustine Hcl197.87.8
Alendronate Sodium1197.87.8
Chlorhexidine Gluconate117.77.7
Lidocaine Hydrochloride And Epinephrine Bitartrate627.57.5
Meclizine Hcl 12.5Mg167.57.5
Meclizine Hcl 25Mg167.57.5
Meclizine Hcl 12.5 Mg167.57.5
Meclizine Hcl 25 Mg167.57.5
Valganciclovir Hydrochloride Powder,147.37.3
Gentamicin157.37.3
Amoxicillin And Clavulanate Potassium317.37.3
Ceftriaxone377.37.3
Clindamycin327.27.2
Lidicaine547.17.1
Burn Relief547.17.1
Lidocaine Hydrochloride And Epinephrine547.17.1
Itraconazole137.17.1
Lidocaine, Menthol547.07.0
Azithromycin Dihydrate626.86.8
Granisetron Hydrochloride116.76.7
Ceftriaxone Sodium406.76.7
Meclizine176.76.7
Clindamycin Phosphate346.56.5
Heparin Sodium146.56.5
Lidocaine586.46.4
Lidocaine 4%546.46.4
Fexofenadine166.26.2
Granisetron106.16.1
Carisoprodol186.06.0
Filgrastim356.06.0
Etonogestrel And Ethinyl Estradiol205.85.8
Ketoconazole Foam135.65.6
Ketoconazole Cream, 2%135.65.6
Hyoscyamine Sulfate85.65.6
Meclizine Hydrochloride175.65.6
Ocrelizumab525.45.4
Meropenem275.45.4
Loratadine Tablet445.35.3
Ibuprofen And Diphenhydramine Citrate195.25.2
Topiramate755.25.2
Valganciclovir155.15.1
Valganciclovir Hydrochloride155.15.1
Vincristine Sulfate235.05.0
Propranolol Hydrochloride554.94.9
Valproic Acid244.94.9
Amlodipine Besylate And Benazepril Hydrochloride74.84.8
Oseltamivir64.84.8
Obinutuzumab124.74.7
Anakinra124.64.6
Sertraline Hydrochloride844.64.6
Daspone74.64.6
Dapsone Gel, 5%74.64.6
Polatuzumab Vedotin74.64.6
Clarithromycin244.54.5
Ondansetron Hydrochloride814.34.3
Cytarabine394.24.2
Human Insulin84.14.1
Omalizumab534.04.0
Levocetirizine Dihydrochloride154.04.0
Misoprostol63.93.9
Bendamustine Hydrochloride73.73.7
Loratadine623.73.7
Ziprasidone Mesylate83.63.6
Erenumab-Aooe303.53.5
Epoprostenol73.43.4
Pyrazinamide53.43.4
Amikacin93.43.4
Somatropin383.33.3
Busulfan83.23.2
Selexipag133.23.2
Loratadine And Pseudoephedrine Sulfate43.23.2
Morphine Sulfate593.13.1
Deferasirox133.13.1
Pegaspargase63.13.1
Bimekizumab103.03.0
Peginterferon Alfa-2A253.03.0
Tofacitinib Citrate62.92.9
Oseltamivir Phosphate112.92.9
Cortisone Acetate52.62.6
Ibrutinib322.52.5
Crizotinib52.52.5
Golimumab332.52.5
Isotretinoin192.52.5
Ivacaftor32.42.4
Diclofenac Potassium42.42.4
Pegvaliase-Pqpz32.32.3
Secukinumab572.32.3
Diclofenac Potassium, Film Coated32.32.3
Diclofenac Potassium Tablets32.32.3
Ixekizumab132.22.2
Daratumumab142.22.2
Lumacaftor And Ivacaftor32.22.2
Fremanezumab-Vfrm42.22.2
Voclosporin32.22.2
Conjugated Estrogens And Medroxyprogesterone Acetate82.22.2
Azacitidine For62.12.1
Lapatinib52.12.1
Crisaborole32.02.0
Medroxyprogesterone Acetate151.91.9
Ofatumumab101.91.9
Guselkumab101.81.8
Emicizumab31.51.5
Orlistat51.21.2
Adapalene30.10.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.